Virus News and Research

Latest Virus News and Research

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

2 Apr 2011
Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

2 Apr 2011
Series of new clinical trials confirm range of viable treatment options for HCV patients

Series of new clinical trials confirm range of viable treatment options for HCV patients

2 Apr 2011
Oral Cancer Awareness Week aims to educate people regarding importance of early detection

Oral Cancer Awareness Week aims to educate people regarding importance of early detection

2 Apr 2011
Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

2 Apr 2011
Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

1 Apr 2011
Biota receives US$231 million BARDA contract to advance laninamivir development

Biota receives US$231 million BARDA contract to advance laninamivir development

1 Apr 2011
Lymphocyte-hepatocyte interactions: Hepatitis C virus changes the rules

Lymphocyte-hepatocyte interactions: Hepatitis C virus changes the rules

1 Apr 2011
Potential HIV vaccine component undergoes dramatic protein rearrangement

Potential HIV vaccine component undergoes dramatic protein rearrangement

1 Apr 2011
Scientists engineer new protein that prevents HIV virus entry into cells

Scientists engineer new protein that prevents HIV virus entry into cells

1 Apr 2011
New research finds HIV virus's V3 loop as attractive vaccine target

New research finds HIV virus's V3 loop as attractive vaccine target

1 Apr 2011
Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

1 Apr 2011
Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

1 Apr 2011
Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex announces final results from Phase 3 REALIZE study against HCV

1 Apr 2011
Biota Scientific receives BARDA contract to develop single-dose antiviral drug

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

1 Apr 2011
Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

1 Apr 2011
Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

1 Apr 2011
Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

1 Apr 2011
Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

31 Mar 2011
Sinovac reports fourth quarter net sales of $9.1 million

Sinovac reports fourth quarter net sales of $9.1 million

31 Mar 2011

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback